0000950170-24-005561.txt : 20240118
0000950170-24-005561.hdr.sgml : 20240118
20240118200008
ACCESSION NUMBER: 0000950170-24-005561
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240116
FILED AS OF DATE: 20240118
DATE AS OF CHANGE: 20240118
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: van Dijk Marcus Antonius
CENTRAL INDEX KEY: 0001881659
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40908
FILM NUMBER: 24543427
MAIL ADDRESS:
STREET 1: 149 FIFTH AVENUE
STREET 2: SUITE 500
CITY: NEW YORK
STATE: NY
ZIP: 10010
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: MiNK Therapeutics, Inc.
CENTRAL INDEX KEY: 0001840229
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 149 FIFTH AVENUE
STREET 2: SUITE 500
CITY: NEW YORK
STATE: NY
ZIP: 10010
BUSINESS PHONE: 212-994-8250
MAIL ADDRESS:
STREET 1: 149 FIFTH AVENUE
STREET 2: SUITE 500
CITY: NEW YORK
STATE: NY
ZIP: 10010
FORMER COMPANY:
FORMER CONFORMED NAME: AgenTus Therapeutics, Inc.
DATE OF NAME CHANGE: 20210112
4
1
ownership.xml
4
X0508
4
2024-01-16
0001840229
MiNK Therapeutics, Inc.
INKT
0001881659
van Dijk Marcus Antonius
149 FIFTH AVENUE, SUITE 500
NEW YORK
NY
10010
false
true
false
false
Chief Scientific Officer
false
Stock Option
0.87
2024-01-16
4
A
false
15000
0.00
A
2034-01-16
Common Stock
15000
15000
D
Stock Option
0.87
2024-01-16
4
A
false
171078
0.00
A
2034-01-16
Common Stock
171078
171078
D
An option to purchase Common Stock was granted to Dr. van Dijk on January 16, 2024 and awarded in accordance with the MiNK Therapeutics, Inc. 2021 Equity Incentive Plan. The option vests over a three-year period, with one-third of the options vesting on the one-year anniversary of the grant date, with the remainder vesting in equal quarterly installments thereafter.
An option to purchase Common Stock was granted to Dr. van Dijk on January 16, 2024 for his performance in 2023, and awarded in accordance with the MiNK Therapeutics, Inc. 2021 Equity Incentive Plan. Half of the options will vest on June 27, 2024 and half of the options will vest on September 27, 2024.
By: /s/ Christine Klaskin, Attorney-in-Fact for Marc Antonius van Dijk
2024-01-18